Accelerate biotechnology

Video: Batavia Biosciences, your biopharmaceutical CDMO

Batavia Biosciences is a biopharmaceutical CDMO with an extensive track record in viral vaccine, viral vector, protein and antibody projects. We aim to significantly contribute to ease human suffering from disease by improving the success rate in the translation of candidate medicines from bench to clinic. We offer our technologies and in-depth knowhow to help…


Webinar: Latest Advancements in Production of Therapeutic Antibodies on E. coli

This webinar will give you insights in the possibilities that E. coli fermentation systems can offer for manufacturing of therapeutic antibodies, including antibody fragments. There will be special focus on our new fermentation technology, SCOPETM  technology: a system for a controlled regulation of protein expression yields in E. coli with a case study to showcase the latest technological advancements….


Article: SIDUS® technology enables first clinical study with live attenuated Zika vaccine

Batavia Biosciences has, with its know-how developed under the SIDUS® technology, extensive expertise in house for the production and testing of viral vector based products, like lentiviral vectors, adenoviral vectors, AAV vectors and Measles vectors. This knowledge covers a broad area; from virus DNA construction and modification, to making research batches and clinical batches, including…


Article: Platform technologies improve protein expression

Platform technologies facilitate development and accelerate commercialization of protein therapeutics. Speed to market is essential in the biopharmaceutical industry today. Manufacturers are seeking mechanisms for increasing efficiencies and reducing costs without compromising the safety and efficacy of their drug products. In addition to exploring novel production methods such as continuous processes and disposable production technology, manufacturers also heavily invest in…


Article: Interview with Alfred Luitjens by Biopharm

Batavia Biosciences uses Biopharm’s BioSolve as process development software. The software enables us to predict the effect of suggested process development steps on, for example the Cost of Goods, and to identify cost drivers. Our Director Cell Technology, Alfred Luitjens was interviewed by Biopharm on how he uses the BioSolve software in his work and…


Article: Tackling the challenges in biosimilar development

Yield is still an area that requires significant improvement for many promising recombinant protein and antibody products. Especially in the field of biosimilars, the ability to manufacture products cost-efficiently has a profound competitive advantage. To facilitate high yield production, Batavia Biosciences has developed STEP®, which enables the creation of stable, mammalian CHO cell lines with…


Article: SIDUS® Technology for viral vector manufacturing

Viral vectors are highly valued in many therapeutic fields given the promise of low cost and safe manufacturing coupled with high product efficacy and an excellent safety profile. Engineered with the use of molecular biology tools, viral vectors from well-known natural viruses such as adeno-associated virus (AAV), lentivirus, adenovirus, or modified vaccinia ankara (MVA) have…


Video: Why Batavia Biosciences is the Best Biotech Company in the Netherlands

Batavia Biosciences was awarded Best Biotech Company of the Netherlands in the NBSA 2016. We aim to significantly contribute to ease human suffering from disease by improving the success rate in the translation of candidate biopharmaceutical medicines from discovery to the clinic. In addition to biopharmaceutical development, we develop leading technologies in support of more affordable medication….


Article: Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based Constructs

Recombinant vectors based on human adenovirus serotype 5 (HAdV-5) have been extensively studied in preclinical models and clinical trials over the past two decades. However, the thorough understanding of the HAdV-5 interaction with human subjects has uncovered major concerns about its product applicability. High vector-associated toxicity and widespread pre-existing immunity have been shown to significantly…


Article: Challenges in Manufacturing Adenoviral Vectors for Global Vaccine Product Deployment

Once adenoviral vector-based vaccines are licensed for the prevention of important infectious diseases, manufacturing processes capable of reliably delivering large numbers of vaccine doses will be required. The highest burden of disease for many infectious pathogens under investigation occurs in resource-poor settings. Therefore, the price per dose will be an important determinant of success. This…